Alumis
Transforming the lives of patients living with immune-mediated diseases using a precision approach.
249 employees · est. 2021 · South San Francisco, United...
Intract Pharma
Transforming Patient Care by Replacing Injections with Safer, More Effective Therapeutics Given Orally.
14 employees · est. 2016 · London, United Kingdom
Intract Pharma is the older company (2021 vs 2016); Alumis is the larger of the two.
Side-by-Side Comparison
| Metric | Alumis | Intract Pharma |
|---|---|---|
| Founded | ||
| Founded | 2021 | 2016 older |
| Headquarters | ||
| Headquarters | South San Francisco, United States | London, United Kingdom |
| Employees | ||
| Employees | 249 larger | 14 |
| Industry | ||
| Industry | Biotechnology, Health Care, Life Sciences | Biotechnology, Life Sciences, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | Series C | Seed |
| Total Funding | ||
| Total Funding | $529.00M | $420.00K |
| Funding Rounds | ||
| Funding Rounds | 3 | 3 |
| Services | ||
| Services | Development of targeted therapies, Clinical trial management, Proprietary data analytics for precision medicine, Patient resources and expanded access policy | Development of oral drug delivery systems, Biotech drug formulations, Collaborative biopharmaceutical research and development, Preclinical research and trials |
| Target Customers | ||
| Target Customers | Patients with immune-mediated diseases, Healthcare providers, Medical researchers, Investors in biotech and pharmaceutical sectors | Pharmaceutical companies, Healthcare providers, Patients requiring biologic therapies, Biotech organizations |
| Taxonomy | ||
| Taxonomy | Immune-mediated Diseases, Precision Medicine, Targeted Therapies, Drug Development, Autoimmune Diseases, Immunology, Pharmaceuticals, Integrated Therapy Development, Immunosuppression Alternatives, Patient-centric Solutions, Disease-specific Drug Targeting, Therapeutic Innovation, Healthcare Analytics | Oral Drug Delivery, Biotechnology Innovation, Monoclonal Antibodies, Gastrointestinal Treatment, Immune-mediated Inflammatory Diseases, Phloral™ Technology, Soteria™ Technology, Protein Delivery, Systemic Immunomodulation, Colon Targeted Delivery, Injectable To Oral Conversion, Biologic Medicines, Proprietary Formulation Technologies, University Spin-out, Pharmaceutical Research And Development |
| Website | ||
| Website | alumis.com | intractpharma.com |
About Alumis
Alumis, founded in 2021 and headquartered in the United States, is making strides in the biotechnology, health care, and life sciences industries. The company is committed to transforming the lives of patients with immune-mediated diseases through a precise, targeted approach. By focusing on optimiz...
About Intract Pharma
Intract Pharma is a dynamic biotechnology company committed to advancing patient care by transforming traditional injectable therapies into oral formulations. Founded in 2016 and headquartered in the United Kingdom, the company is pioneering innovations in the oral delivery of complex proteins, part...
Be first to know when either one moves
Funding rounds, hiring surges, leadership changes and stack switches at Alumis and Intract Pharma — tracked continuously, sent the day they land.
Funding, hiring, leadership and stack changes at Alumis and Intract Pharma — by email.
Frequently Asked Questions
Compare Alumis with someone else
Start typing a company name or domain.